Introduction
============

Urinary tract infections (UTIs) are among the most common bacterial infections acquired in the general population and in hospitals ([@b1-etm-0-0-8252]). A variety of pathogens, including bacteria, fungi, mycoplasma, chlamydia and viruses, may cause UTIs, which are mainly characterized by painful, frequent and urgent urination, as well as urethral burning ([@b2-etm-0-0-8252]). In the USA, \>7 million outpatients and \~1 million in-patients with UTIs are encountered in the clinic each year ([@b3-etm-0-0-8252]), while \~150 million patients are diagnosed with UTIs worldwide each year ([@b4-etm-0-0-8252]). UTIs, which may cause septic shock, rank third among all diseases that may lead to death as a result of infection ([@b5-etm-0-0-8252]). Gram-negative bacteria are the major cause of community-acquired and hospital-acquired UTIs ([@b4-etm-0-0-8252],[@b6-etm-0-0-8252]). At present, antibiotics are the major treatment for UTIs, but not all patients benefit from them. Abuse of antibiotics markedly increases the drug resistance of bacteria, reduces the clinical efficacy of antibiotics and increases the recurrence rate of bacterial infection, which wastes medical resources and reduces the quality of life of patients ([@b7-etm-0-0-8252]). Multiple Chinese traditional medicines have been demonstrated to exert bacteriostatic effects on pathogenic microorganisms, and may therefore inhibit or destroy the formation of toxic substances ([@b8-etm-0-0-8252],[@b9-etm-0-0-8252]). A test of antibacterial properties in mice revealed that Sanjin tablet (SJTs) has a marked bacteriostatic effects ([@b10-etm-0-0-8252]).

SJT is composed of five types of Chinese herbal medicines: Baqia (Chinaroot Greenbrier Rhizome), Jinyinggen (Root of Cherokee Rose), Yangkaikou (Fruit of Fiverleaf Akebia), Jinshateng (Lygodii Herba) and Jixuecao (Asiatic Pennywort Herb), which were recorded in the Chinese Pharmacopoeia 2015 ([@b11-etm-0-0-8252]). According to the concepts of Chinese Traditional Medicine, the herbal components have the following properties: Jinyinggen is acerb and neutral in nature, and is able to control nocturnal emission and astringent intestine ([@b12-etm-0-0-8252]). Baqia is bitter and neutral in nature; it is able to alleviate rheumatism, promote blood circulation, detoxicate, relieve convulsion and calm endogenous wind ([@b13-etm-0-0-8252]). Jinshateng is slightly sweet and cold-natured, and is able to clear heat, detoxicate and remove dampness ([@b14-etm-0-0-8252]). These three herbs are monarch drugs (major components) in the prescription, which have an enhancing effect on the functions of anti-inflammation, dehumidification and detoxification ([@b15-etm-0-0-8252]). The above three drugs supplemented with Yangkaikou and Jixuecao exhibit enhanced effects against UTIs ([@b16-etm-0-0-8252],[@b17-etm-0-0-8252]).

Previous clinical studies have demonstrated that SJTs are able to reduce the symptoms of chronic UTIs, the number of recurrences and the secretory level of urinary soluble interleukin (IL)-2 receptor, IL-6 and IL-8 in patients with chronic nephropyelitis ([@b10-etm-0-0-8252]). Electron microscopy revealed that SJTs is able to make the flagella of *Escherichia coli* drop ([@b18-etm-0-0-8252]). Lower UTIs mainly comprise cystitis and urethritis, which have high incidence and recurrence rates. In recent years, numerous clinical studies have explored the efficacy and safety of SJTs combined with antibiotics in the treatment of acute lower UTIs (ALUTIs) in China. However, there is no meta-analysis on SJTs combined with antibiotics for the treatment of ALUTIs. To the best of our knowledge, the present study is the first comprehensive systematic review that determined the efficacy and safety of SJTs combined with antibiotics for the treatment of ALUTIs. The Grading of Recommendations, Assessment, Development and Evaluations (GRADE) system ([@b19-etm-0-0-8252],[@b20-etm-0-0-8252]) was used to evaluate the quality of evidence of the key outcomes of the present meta-analysis, which provides a basis and serves as a reference for clinical practice guidance.

Materials and methods
=====================

### Search strategy

Electronic databases, including PubMed, EMBASE, Cochrane Library, Web of Science, China National Knowledge Infrastructure, Chinese BioMedical Database, WanFang Database and VIP Database (VIP) were systematically searched for entries added between inception and December 2018. The following search terms were used separately or in combination: 'Sanjin' or 'Sanjin tablet' AND 'acute lower urinary tract infection' or 'acute lower UTI'.

### Selection criteria

Studies were selected according to the following inclusion criteria: i) Participants were diagnosed with ALUTIs; ii) the study was performed as a randomized controlled trial (RCT); iii) efficacy of SJT combined with antibiotics vs. antibiotics, including levofloxacin tablets (LTs), gatifloxacin tablets (GTs) and ofloxacin tablets (OTs); iv) primary outcomes were the cure rate (i.e. the symptoms disappeared and the leukocyte levels in the urine returned to normal after treatment) and the recurrence rate (i.e. the symptoms of the patients reappeared or their urine leukocyte value increased again); and v) secondary outcomes included the total effective rate (i.e. the symptoms partially disappeared or the value of urine leukocytes was reduced but did not return to normal after treatment), bacterial clearance rate (the original infected part of the specimen did not regenerate after treatment), incidence of adverse reactions (ADRs) and any adverse events (ADEs), including headache, stomach ache, stomach discomfort, mild nausea, skin rash and dizziness.

The exclusion criteria were as follows: i) Insufficient data (miscalculation or missing data); ii) the full text was not available; iii) duplicated data; and iv) the intervention included other Chinese drugs, acupuncture and massage (including a proprietary Chinese drug, Traditional Chinese Medicine extract injection, decoction, auricular points and other Traditional Chinese Medicine methods as auxiliary treatment).

### Literature screening

EndNote (v. 8.1.11010; Clarivate Analytics) was used to identify duplicates among the studies retrieved. After reading the titles and abstracts of the studies obtained for preliminary screening, those articles that did not meet the inclusion criteria were excluded. The full text of the articles that potentially met the inclusion criteria was further screened to determine whether they should be included in the present study. The list of references of the studies retrieved were also checked to identify any further studies. The literature was independently screened by two researchers (JL and MS) according to the inclusion/exclusion criteria. Any disagreement between the reviewers was resolved by consulting a third party (LW and YX).

### Data extraction

Two independent researchers, namely JL and MS, were responsible for data extraction and any disagreements were resolved by a third author (YX). The number of events and the total number of patients in each group were extracted from binary outcomes. The mean, standard deviation and sample size for each group were extracted or inputted from continuous outcomes. The data extracted included the following: Name of the first author, year of publication, method of randomization, number of patients, sex and age in the comparison groups, as well as the total number of patients, the drug dose and duration of treatment in the comparison groups, primary and secondary outcomes, and any ADEs or ADRs. When the study had ≥1 common intervention group, the method recommended by the Cochrane Collaboration was followed, i.e. grouping and merging, and conversion of the multi-arm trial into a 2-arm trial ([@b21-etm-0-0-8252]).

### Quality assessment

The Cochrane Handbook for Systematic Reviews of Interventions 5.1 'bias risk assessment' tool was used to assess quality in seven domains: Random sequence generation; allocation concealment; blinding of participants and personnel; blinding of outcome assessment; incomplete outcome data; selective outcome reporting; and other bias ([@b21-etm-0-0-8252]). The risk of bias was classified as low, high or unclear. JL and CZ were responsible for independent assessment of quality and any disagreements were resolved by a third author (YX).

### Statistical analysis

RevMan 5.3, provided by the Cochrane Collaboration Network, was used for meta-analysis. The relative ratio (RR) and 95% CI were used for binary outcomes and the weighted mean difference and 95% CIs were used for continuous outcomes. The I^2^ statistic was used to assess heterogeneity; if I^2^\<50%, the statistical homogeneity was considered to be acceptable and the fixed-effects model was used, and if I^2^≥50%, a significant statistical heterogeneity was assumed and the random-effects model was adopted. If the study was not suitable for meta-analysis, a descriptive analysis was performed. A funnel plot was used to detect publication bias.

### Subgroup and sensitivity analyses

In order to address heterogeneity, subgroup analysis was performed, which focused on the cure rate of the different interventions. Interventions included SJTs combined with GTs vs. GTs and SJTs combined with LTs vs. LTs. Sensitivity analysis was performed to assess the influence of a single study on the overall pooled estimate by removing one study at a time.

### GRADE assessment

The GRADE system was used to classify the quality of evidence of the cure rate, total effective rate, recurrence rate and incidence of ADRs. According to the GRADE classification method, the RCTs are initially classified as studies with the highest quality of evidence and their quality was then decreased based on 5 factors (risk of bias, inconsistency, indirectness, imprecision and publication bias), and the quality of the final evidence was classified as high, moderate, low and very low ([@b19-etm-0-0-8252],[@b20-etm-0-0-8252]).

Results
=======

### Literature search results

The initial literature search identified 64 studies. After duplicates among different databases were removed by using EndNote, the title and abstract of the studies were read, and the inclusion and exclusion criteria were combined, and 36 articles were selected for evaluation of their full text. A total of 28 articles were excluded for not being RCTs (n=16), not correctly performing intervention measures (n=3), unavailability of data (n=5) and containing duplicate or incorrect data (n=4). A total of 8 trials were eventually selected for inclusion in the present meta-analysis, all of which were published in Chinese ([@b22-etm-0-0-8252]--[@b29-etm-0-0-8252]). The selection process of the studies is presented in [Fig. 1](#f1-etm-0-0-8252){ref-type="fig"}.

### Characteristics of the studies included

A total of 8 studies were included in the present meta-analysis, all of which described that the baseline values of the experimental and control groups were comparable. All patients included in the present meta-analysis underwent a urine culture test at the time-point of diagnosis. After treatment, a urine culture test was performed to determine the curative effect. A change in urine bacterial culture for the same strain from positive to negative was considered to indicate cure. In total, 3 studies were 3-arm trials ([@b22-etm-0-0-8252],[@b23-etm-0-0-8252],[@b28-etm-0-0-8252]), and 2 of them were double-blinded and double-simulated studies ([@b22-etm-0-0-8252],[@b23-etm-0-0-8252]). After grouping and combining these 3-arm trials, the interventions were as follows: SJTs vs. antibiotics and SJTs combined with antibiotics vs. antibiotics. The interventions of the other 5 studies were SJTs combined with antibiotics vs. antibiotics. Other conventional and adjuvant treatments were not mentioned in any of the studies. The total sample size was 790 cases, including 405 cases in the experimental group and 385 cases in the control group. The average daily dose of SJTs was 12 pills (3.48 g). In 5 studies, patients received treatment for 7 days, while in other studies, patients received treatment for 3 ([@b27-etm-0-0-8252]), 5 ([@b17-etm-0-0-8252]) and 3--15 days ([@b26-etm-0-0-8252]). A total of 7 trials reported on ADEs/ADRs. The characteristics of the 8 trials included are listed in [Table I](#tI-etm-0-0-8252){ref-type="table"}.

### Methodological quality

None of the 8 studies reported on the study protocol, sample size estimates, randomization, blinding or allocation concealment. A total of 6 studies mentioned that the patients were followed up after treatment to evaluate recurrence, but only 3 studies had followed up data ([@b17-etm-0-0-8252],[@b27-etm-0-0-8252],[@b28-etm-0-0-8252]). In total, 6 studies reported on withdrawals and loss to follow-up, but no intention analysis was performed ([@b22-etm-0-0-8252]--[@b25-etm-0-0-8252],[@b27-etm-0-0-8252],[@b28-etm-0-0-8252]). One study did not fully report on pre-specified outcomes and exhibited selective reporting of results ([@b24-etm-0-0-8252]). The results of the quality assessment of the studies included are provided in [Figs. 2](#f2-etm-0-0-8252){ref-type="fig"} and [3](#f3-etm-0-0-8252){ref-type="fig"}.

Meta-analysis
-------------

### Cure rate

The cure rate was assessed for a total of 790 patients across all of the studies included. In total, 7 studies ([@b17-etm-0-0-8252],[@b22-etm-0-0-8252]--[@b25-etm-0-0-8252],[@b27-etm-0-0-8252],[@b28-etm-0-0-8252]) were divided into 2 subgroups according to the different interventions and the homogeneity was good in each subgroup (P=0.73/0.72, I^2^=0). The fixed-effects model was used for the meta-analysis. The results indicated that the cure rate of SJTs combined with GTs was higher than that of GTs alone (RR=1.30, 95% CI=1.07--1.57, P=0.009; [Fig. 4](#f4-etm-0-0-8252){ref-type="fig"}), and the cure rate of SJTs combined with LTs was higher than that of LTs alone (RR=1.13, 95% CI=1.04--1.24, P=0.006; [Fig. 4](#f4-etm-0-0-8252){ref-type="fig"}). One study ([@b26-etm-0-0-8252]) performed a descriptive analysis and suggested that the cure rate of SJTs combined with OT was higher than that of OT alone (RR=1.38, 95% CI=1.03--1.84, P\<0.03).

### Total effective rate

A total of 510 patients from 5 studies were assessed for the total effective rate. The intervention of 3 studies consisted of SJTs combined with LTs vs. LTs alone ([@b22-etm-0-0-8252],[@b27-etm-0-0-8252],[@b28-etm-0-0-8252]). The heterogeneity test indicated that the fixed-effects model was appropriate for use (P=0.25, I^2^=29%). Meta-analysis demonstrated that the total effective rate of SJTs combined with LTs was higher than that of LTs alone (RR=1.11, 95% CI=1.03--1.19, P=0.005; [Fig. 5](#f5-etm-0-0-8252){ref-type="fig"}). Analysis of the data of one study ([@b17-etm-0-0-8252]) suggested that the effective rate of SJTs combined with GTs was higher than that of GTs alone (RR=1.31, 95% CI=1.03--1.67, P=0.03). One study ([@b26-etm-0-0-8252]) suggested that the total effective rate of SJTs combined with OT and that of OTs alone was not significantly different (RR=1.16, 95% CI=0.95--1.41; P=0.14).

### Recurrence rate

A total of 3 studies comprising 201 patients were assessed regarding the recurrence rate ([@b17-etm-0-0-8252],[@b27-etm-0-0-8252],[@b28-etm-0-0-8252]). The interventions were SJTs combined with GTs vs. GTs and SJTs combined with LTs vs. LTs. In order to comprehensively evaluate the effect of SJT combined with antibiotics, the 3 interventions were classified as SJT combined with antibiotics vs. antibiotics alone for combined analysis. The homogeneity of the 3 studies was good (P=0.69, I^2^=0%) and the fixed-effects model was used for the meta-analysis. Statistical analysis indicated that the recurrence rate of SJT combined with antibiotics was lower than that of antibiotics alone (RR=0.35, 95% CI=0.13--0.97, P=0.04; [Fig. 6](#f6-etm-0-0-8252){ref-type="fig"}).

### Bacterial clearance rate

Bacterial clearance rates were reported in two studies ([@b20-etm-0-0-8252],[@b22-etm-0-0-8252]). The interventions were SJTs combined with LTs vs. LTs and SJTs combined with GTs vs. GTs, respectively. The interventions were classified as SJT combined with antibiotics vs. antibiotics to comprehensively evaluate the combined effect. The fixed-effects model was used for analysis (P=0.36, I^2^=0%), revealing that the bacterial clearance rate of SJT combined with antibiotics was higher than that of antibiotics alone (RR=1.41, 95% CI=1.09--1.84, P=0.009; [Fig. 7](#f7-etm-0-0-8252){ref-type="fig"}).

### Incidence of ADRs

A total of four studies reported on the incidence of ADRs ([@b20-etm-0-0-8252],[@b22-etm-0-0-8252],[@b27-etm-0-0-8252],[@b28-etm-0-0-8252]). The combined antibiotics in the four studies included LTs, GTs and OTs. The homogeneity among the studies was good (P=0.34, I^2^=11%), and the fixed-effects model was used for the meta-analysis. The results demonstrated that there was no significant difference in the incidence of ADRs between SJT combined with antibiotics and antibiotics alone (RR=0.61, 95% CI=0.32--1.17; P=0.14; [Fig. 8](#f8-etm-0-0-8252){ref-type="fig"}).

### ADRs/ADEs

In total, seven studies (710 cases) mentioned observation regarding ADRs or ADEs and three studies ([@b23-etm-0-0-8252]--[@b25-etm-0-0-8252]) reported positive results. A study ([@b22-etm-0-0-8252]) reported on one case of slight increase in total bilirubin, one case of slight decrease in blood leukocytes and one case of proneness to hunger in the SJT group, as well as one case of headache, one case of stomach ache and one case of elevated blood pressure in the LT group, and one case of thirst and proneness to hunger in the combined group. Another study ([@b17-etm-0-0-8252]) reported two cases of nausea and stomach discomfort, and two cases of mild diarrhea in the experimental group, in addition to five cases of nausea and stomach discomfort, three cases of loss of appetite and three cases of mild dysuria in the control group. In addition, one study ([@b27-etm-0-0-8252]) reported five cases of mild nausea and dizziness in the experimental and control groups, respectively. Another study ([@b28-etm-0-0-8252]) reported three cases of stomach discomfort and one case of skin rash in the combined treatment group, one case of stomach discomfort in the SJT group and two cases of stomach discomfort in the LT group.

### Publication bias

The funnel plot was asymmetric when pooling seven trials on the cure rate ([Fig. 9](#f9-etm-0-0-8252){ref-type="fig"}). The potential publication bias may be due to the high proportion of published positive results in China. All of the studies included in the present meta-analysis are written in Chinese, which may cause linguistic publication bias.

### Sensitivity analysis

A sensitivity analysis of the six trials with incomplete reporting was performed ([@b22-etm-0-0-8252]--[@b25-etm-0-0-8252],[@b27-etm-0-0-8252],[@b28-etm-0-0-8252]) using Revman software. The P-value of the overall pooled estimate changed significantly after removing one study at a time regarding four outcomes (cure rate, total effective rate, recurrence rate, incidence of adverse reactions). The results of the sensitivity analysis indicated that the sensitivity was high and the results of the meta-analysis were not stable and reliable. This suggests that the present results require confirmation using high-quality RCTs and larger samples. Clinicians should therefore exercise caution when using the present results. The P-values obtained in the sensitivity analysis for the six trials with incomplete reporting are provided in [Table II](#tII-etm-0-0-8252){ref-type="table"}.

### GRADE evidence profile

The quality of evidence for the cure rate, total effective rate, recurrence rate and incidence of ADRs was very low, low, very low and low, respectively, due to the lack of randomization, blinding and allocation concealment, small sample size and publication bias, respectively. The GRADE evidence profiles are provided in [Table III](#tIII-etm-0-0-8252){ref-type="table"}.

Discussion
==========

The purpose of the present meta-analysis was to evaluate the efficacy of SJT combined with antibiotics in the treatment of ALUTIs. In order to provide accurate evidence for clinical practice, the cure rate and total effective rate were assessed. Under the same curative effect standard, combined analysis of 3 studies revealed that the cure rate of SJT combined with GT was higher than that of GT alone, while combined analysis of 4 studies indicated that the cure rate of SJT combined with LT was higher than that of LT alone. In addition, 1 study indicated that the cure rate of SJT combined with OT was higher than that of OT alone. Combined analysis of 3 studies suggested that the total effective rate of SJT combined with LT was higher than that of LT alone and 1 study indicated that the total effective rate of SJT combined with GT was higher than that of GT alone. Combined analysis of 3 studies revealed that the recurrence rate of SJT combined with antibiotics was lower than that of antibiotics alone. Combined analysis of 2 studies indicated that the bacterial clearance rate of SJT combined with antibiotics was higher than that of antibiotics alone. The present meta-analysis demonstrated that SJT combined with antibiotics improved the clinical curative effect in the treatment of ALUTIs. Addition of SJT to antibiotics significantly improved the cure, total effective and bacterial clearance rates, and decreased the recurrence rate. However, the sensitivity analysis suggested that the stability and reliability of the results were poor. More RCTs with better consistency and fewer confounding factors are required to further verify the results, so as to provide reliable evidence for clinical practice.

The incidence of ADRs reported in the studies was summarized. The results of 4 studies suggested that there was no significant difference between SJT plus antibiotics and antibiotics alone regarding the incidence of ADRs. Thus, the addition of SJT to antibiotics may not increase the incidence of ADRs. No ADRs were reported in 3 studies, while 4 studies reported a slight increase in total bilirubin, a mild decrease in blood leukocytes, increased hunger, headache, stomach ache, elevated blood pressure, thirst, nausea, stomach discomfort, mild diarrhea and reduced appetite, mild dysuria and skin rash in the control groups. All ADRs were minor or tolerable and commonly disappeared naturally or after drug withdrawal. There were no serious ADRs or ADEs reported in any of the trials included. However, the methodological quality of the studies included in the present analysis was poor and safety requires to be further clarified by standard centralized monitoring of hospital patients.

In terms of the cure rate, this was significantly higher in the experimental group compared with that in the control group. However, there was a marked risk of bias caused by blinding, randomization, allocation concealment and publication bias. Inaccuracy due to small sample size was also present. According to the 5 degradation factors (risk of bias, inconsistency, indirectness, imprecision and reporting bias) in the GRADE system, the quality of evidence for the cure rate of SJT combined with antibiotics for ALUTI was very low and low, respectively. The total effective rate in the experimental group was higher than that in the control group; however, due to the risk of bias caused by the lack of blinding, randomization, allocation concealment and publication bias due to the small sample size, the quality of evidence for the total effective rate of SJT combined with LTs for ALUTIs decreased from high to low. Meta-analysis demonstrated that the recurrence rate of SJT combined with antibiotics was lower than that of antibiotics alone. However, the quality of evidence decreased from high to very low due to the risk of bias caused by blinding, randomization, allocation concealment, imprecision and publication bias caused by the small sample size. The quality of evidence regarding the incidence of ADRs was low due to the risk of bias caused by blinding, randomization, allocation concealment and publication bias. The results of the evaluation of the quality of evidence of the above outcomes should be combined with factors including the patients\' value intention and cost in order to provide recommendations, and serve as a reference or basis for clinical practice guidance.

The major limitations of the present study are as follows: i) None of the studies included reported blinding, randomization or allocation concealment, which may result in risk of bias; ii) study protocol, informed consent or ethical statements were not specified in any of the studies; iii) 6 studies reported that follow-up was performed after treatment to evaluate recurrence, but only 3 studies included follow-up data and it was not possible to evaluate the long-term effect in the cohorts of the other studies; iv) 6 studies reported on case shedding, all of which failed to perform an intentionality analysis and had incomplete reports; v) 1 study did not fully report on pre-specified outcomes and featured selective reporting; vi) no sample size estimation was reported in any of the studies included. Specifically, 3 studies had a sample size ≥100 cases and 5 studies had a sample size ≤80 cases. In various studies, the curative effect index was unstable and the test efficiency was low due to the small sample size. The overall methodological quality of the studies included was low. It has been suggested that large-sample, low-bias clinical RCTs should first refer to Consolidated Standards of Reporting Trials ([@b29-etm-0-0-8252]).

The results of the present meta-analysis suggested that, in clinical practice, addition of SJT to the use of antibiotics may be considered in order to improve the curative effect and reduce the recurrence rate in patients with ALUTIs. Due to the poor methodological quality of the studies included, the results of the present meta-analysis require to be further confirmed. The level of evidence obtained in the present study is low; thus, the expert consensus method was employed to confirm whether it may be widely used in the clinic, including the nominal group and Delphi methods. Clinicians should interpret the results of the present study with caution with regard to the actual situation and perform clinical treatments based on comprehensive consideration of evidence, expert consensus, clinical experience and the patients\' preferences. In the present study, the patients were not divided into those with complex and simple LUTIs. A previous meta-analysis focused on simple LUTIs ([@b30-etm-0-0-8252]). In the future, the exact efficacy of SJT for complex LUTIs may be further explored.

In conclusion, the present meta-analysis demonstrated that, compared with antibiotics treatment, SJT combined with antibiotics improved the cure rate, total effective rate and bacterial clearance rate, and decreased the recurrence rate without any serious ADRs in patients with ALUTIs. However, the GRADE quality of evidence was low. Thus, additional large-sample, high-quality RCTs with a rigorous design are required to improve the quality of evidence.
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###### 

Characteristics of trials included.

                                                             Sample size              Treatment group                                                                                                                                                                                                                                                                                                                         
  ---------------------------------------------------------- ------------- ---- ----- ----------------- -------------------------- ----- --------------- ----------------------- ------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -----------------------
  Liu (2017)^[a](#tfn1-etm-0-0-8252){ref-type="table-fn"}^   72            72   144   T:28/42           T:20 to 74 (39.70±14.37)   12    SJP + LT        SJP placebo + LT 0.4g   7       ^[b](#tfn2-etm-0-0-8252){ref-type="table-fn"}--[f](#tfn6-etm-0-0-8252){ref-type="table-fn"}^                                                                                                                                         ([@b22-etm-0-0-8252])
                                                                                      C:27/44           C:18 to 73 (39.14±15.82)         placebo 0.4g                                                                                                                                                                                                                                                                         
                                                             72            72   144   T:22/50           T:18 to 75 (35.90±14.14)   12    SJT + LT 0.4g   SJP placebo + LT 0.4g                                                                                                                                                                                                                                                
                                                                                      C:27/44           C:18 to 73 (39.14±15.82)                                                                                                                                                                                                                                                                                              
  Lyu (2015)^[a](#tfn1-etm-0-0-8252){ref-type="table-fn"}^   71            72   143   T:29/42           T:(39.00)                  12    SJP + LT        SJP placebo + LT 0.4g   7       ^[b](#tfn2-etm-0-0-8252){ref-type="table-fn"},[f](#tfn6-etm-0-0-8252){ref-type="table-fn"}^                                                                                                                                          ([@b23-etm-0-0-8252])
                                                                                      C:27/45           C:(39.00)                        placebo 0.4g                                                                                                                                                                                                                                                                         
                                                             72            72   144   T:22/50           T:(35.00)                  12    SJT + LT 0.4g   SJP placebo + LT 0.4g                                                                                                                                                                                                                                                
                                                                                      C:27/45           C:(39.00)                                                                                                                                                                                                                                                                                                             
  Hu (2014)                                                  40            40   80    T:0/40            20 to 50 (35.40±2.70)      15    SJP + GT 0.4g   GT 0.4g                 7       ^[b](#tfn2-etm-0-0-8252){ref-type="table-fn"},[f](#tfn6-etm-0-0-8252){ref-type="table-fn"}^                                                                                                                                          ([@b24-etm-0-0-8252])
                                                                                      C:0/40                                                                                                                                                                                                                                                                                                                                  
  Zheng (2013)                                               38            38   76    T:12/26           T:20 to 58 (30.80±5.70)      9   SJP + GT 0.4g   GT 0.4g                 5       ^[b](#tfn2-etm-0-0-8252){ref-type="table-fn"}--[g](#tfn7-etm-0-0-8252){ref-type="table-fn"}^                                                                                                                                         ([@b17-etm-0-0-8252])
                                                                                      C:14/24           C:21 to 60 (31.30±4.90)                                                                                                                                                                                                                                                                                               
  Wang (2011)                                                28            28   56    T:0/28            T:20 to 49 (33.00±6.23)    15    SJP + GT 0.4g   GT 0.4g                 7       ^[b](#tfn2-etm-0-0-8252){ref-type="table-fn"},[f](#tfn6-etm-0-0-8252){ref-type="table-fn"}^                                                                                                                                          ([@b25-etm-0-0-8252])
                                                                                      C:0/28            C:18 to 47 (32.00±5.46)                                                                                                                                                                                                                                                                                               
  Tu (2011)                                                  40            40   80    T:7/33            T:16 to 50 (46.10)         12    SJP + OT 0.4g   OT 0.4g                 3--15   ^[b](#tfn2-etm-0-0-8252){ref-type="table-fn"},[c](#tfn3-etm-0-0-8252){ref-type="table-fn"}^                                                                                                                                          ([@b26-etm-0-0-8252])
                                                                                      C:7/33            C:16 to 50 (48.10)                                                                                                                                                                                                                                                                                                    
  Qiu (2009)                                                 80            60   140   T:0/80            T:22 to 63 (33.70±15.90)   12    SJP + LT 0.4g   LT 0.4g                 3       ^[b](#tfn2-etm-0-0-8252){ref-type="table-fn"},[c](#tfn3-etm-0-0-8252){ref-type="table-fn"},[e](#tfn5-etm-0-0-8252){ref-type="table-fn"},[f](#tfn6-etm-0-0-8252){ref-type="table-fn"}^                                                ([@b27-etm-0-0-8252])
                                                                                      C:0/60            C:-                                                                                                                                                                                                                                                                                                                   
  ^[a](#tfn1-etm-0-0-8252){ref-type="table-fn"}^Mei (2008)   35            35   70    T:13/22           T:19 to 61 (47.00)         12    SJP             LT 0.4g                 7       ^[b](#tfn2-etm-0-0-8252){ref-type="table-fn"},[c](#tfn3-etm-0-0-8252){ref-type="table-fn"},[e](#tfn5-etm-0-0-8252){ref-type="table-fn"},[f](#tfn6-etm-0-0-8252){ref-type="table-fn"},[g](#tfn7-etm-0-0-8252){ref-type="table-fn"}^   ([@b28-etm-0-0-8252])
                                                                                      C:14/21           C:20 to 59 (47.00)                                                                                                                                                                                                                                                                                                    
                                                             35            35   70    T:15/20           T:20 to 60 (43.00)         12    SJP + LT 0.4g   LT 0.4g                                                                                                                                                                                                                                                              
                                                                                      C:14/21           C:20 to 59 (47.00)                                                                                                                                                                                                                                                                                                    

three-arm trial

cure rate

total effective rate

bacterial clearance rate

incidence of adverse reactions

ADRs/ADEs

recurrence rate; T, treatment group; C, control group; SJT, Sanjin tablet; LT, levofloxacin tablet; GT, gatifloxacin tablet; OT, oxyfluoxacin tablet.

###### 

Sensitivity analysis of six trials with incomplete reporting.

  Outcome                                                              Study removed \[first author (year)\]   P-value   RR (95% CI)
  -------------------------------------------------------------------- --------------------------------------- --------- -------------------
  Cure rate (SJT + LT vs. LT)                                          Liu (2017)                              0.008     1.13 (1.03--1.23)
  Cure rate (SJT + LT vs. LT)                                          Lyu (2015)                              0.060     1.11 (1.00--1.24)
  Cure rate (SJT + LT vs. LT)                                          Qiu (2009)                              0.010     1.17 (1.03--1.31)
  Cure rate (SJT + LT vs. LT)                                          Mei (2008)                              0.010     1.13 (1.02--1.25)
  Cure rate (SJT + GT vs. GT)                                          Hu (2014)                               0.140     1.22 (0.94--1.58)
  Cure rate (SJT + GT vs. GT)                                          Wang (2011)                             0.030     1.31 (1.02--1.67)
  Total effective rate (SJT + LT vs. LT)                               Liu (2017)                              0.050     1.07 (1.00--1.15)
  Total effective rate (SJT + LT vs. LT)                               Qiu (2009)                              0.010     1.15 (1.04--1.29)
  Total effective rate (SJT + LT vs. LT)                               Mei (2008)                              0.020     1.10 (1.02--1.19)
  Recurrence rate (SJT + LT vs. LT)                                    Mei (2008)                              0.110     0.38 (0.12--1.22)
  Bacterial clearance rate (SJT + LT vs. LT)                           Liu (2017)                              0.040     1.32 (1.02--1.71)
  Incidence of adverse reactions (SJT + antibiotics vs. antibiotics)   Liu (2017)                              0.220     0.66 (0.33--1.29)
  Incidence of adverse reactions (SJT + antibiotics vs. antibiotics)   Zheng (2013)                            0.740     0.87 (0.37--2.02)
  Incidence of adverse reactions (SJT + antibiotics vs. antibiotics)   Qiu (2009)                              0.140     0.56 (0.26--1.21)
  Incidence of adverse reactions (SJT + antibiotics vs. antibiotics)   Mei (2008)                              0.040     0.47 (0.23--0.98)

Antibiotics included levofloxacin tablets (LTs), gatifloxacin tablet (GTs) and oxyfluoxacin tablets (OTs). CI, confidence interval; RR, relative ratio.

###### 

GRADE evidence profile: SJT plus antibiotics for acute lower urinary tract infection.

                                                                                                         Quality assessment   No. of patients     Effect                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  ------------------------------------------------------------------------------------------------------ -------------------- ------------------- -------------------------------------------------------- -------------------------- ------------------------- -------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------ ------------------ ------------------- ------------------------------------------------- ---------- ----------
  Cure rate-SJTs combined with GTs vs. GTs (7 days)                                                      3                    Randomized trials   Serious^[a](#tfn10-etm-0-0-8252){ref-type="table-fn"}^   No serious inconsistency   No serious indirectness   Serious^[b](#tfn11-etm-0-0-8252){ref-type="table-fn"}^   Reporting bias^[c](#tfn12-etm-0-0-8252){ref-type="table-fn"},[g](#tfn16-etm-0-0-8252){ref-type="table-fn"}^                                                 79/106 (74.50%)    61/106 (57.50%)    1.3 (1.07--1.57)    173 more per 1,000 (from 40 more to 328 more)     Very low   Critical
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        60%                                    180 more per 1,000 (from 42 more to 342 more)                
  Cure rate-SJT combined with LT vs. LT (7 days)                                                         4                    Randomized trials   Serious^[a](#tfn10-etm-0-0-8252){ref-type="table-fn"}^   No serious inconsistency   No serious indirectness   No serious imprecision                                   Reporting bias^[c](#tfn12-etm-0-0-8252){ref-type="table-fn"},[d](#tfn13-etm-0-0-8252){ref-type="table-fn"},[g](#tfn16-etm-0-0-8252){ref-type="table-fn"}^   218/259 (84.20%)   175/238 (73.50%)   1.13 (1.04--1.24)   96 more per 1,000 (from 29 more to 176 more)      Low        Critical
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        76.10%                                 99 more per 1,000 (from 30 more to 183 more)                 
  Total effective rate-SJT combined with LT vs. LT (follow-up mean 7 days)                               3                    Randomized trials   Serious^[a](#tfn10-etm-0-0-8252){ref-type="table-fn"}^   No serious inconsistency   No serious indirectness   No serious imprecision                                   Reporting bias^[c](#tfn12-etm-0-0-8252){ref-type="table-fn"},[d](#tfn13-etm-0-0-8252){ref-type="table-fn"}^                                                 177/187 (94.70%)   141/166 (84.90%)   1.11 (1.03--1.19)   93 more per 1,000 (from 25 more to 161 more)      Low        Critical
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        85.70%                                 94 more per 1,000 (from 26 more to 163 more)                 
  Recurrence rate-SJT combined with antibiotics vs. antibiotics (follow-up mean 7 days)                  3                    Randomized trials   Serious^[a](#tfn10-etm-0-0-8252){ref-type="table-fn"}^   No serious inconsistency   No serious indirectness   Serious^[b](#tfn11-etm-0-0-8252){ref-type="table-fn"}^   Reporting bias^[c](#tfn12-etm-0-0-8252){ref-type="table-fn"}--[e](#tfn14-etm-0-0-8252){ref-type="table-fn"}^                                                4/115 (3.50%)      10/86 (11.60%)     0.35 (0.13--0.97)   76 fewer per 1,000 (from 3 fewer to 101 fewer)    Very low   Critical
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        18.80%                                 122 fewer per 1,000 (from 6 fewer to 164 fewer)              
  Incidence of adverse reactions-SJT combined with antibiotics vs. antibiotics (follow-up mean 7 days)   4                    Randomized trials   Serious^[a](#tfn10-etm-0-0-8252){ref-type="table-fn"}^   No serious inconsistency   No serious indirectness   No serious imprecision                                   Reporting bias^[c](#tfn12-etm-0-0-8252){ref-type="table-fn"},[d](#tfn13-etm-0-0-8252){ref-type="table-fn"},[f](#tfn15-etm-0-0-8252){ref-type="table-fn"}^   14/225 (6.20%)     21/205 (10.20%)    0.61 (0.32--1.17)   40 fewer per 1,000 (from 70 fewer to 17 more)     Low        Critical
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        7%                                     27 fewer per 1,000 (from 48 fewer to 12 more)                

'High quality', further research is unlikely to change the confidence in the estimate of the effect; 'moderate quality', further research is may have a significant impact on the confidence in the estimate of the effect and may change the estimate; 'low quality', further research is likely to have a significant impact on the confidence in the estimate of the effect and is likely to change the estimate; 'very low quality', high uncertainty regarding the estimate.

Lack of randomization, blinding and allocation concealment.

The sample size included in the study is too small to improve imprecision.

Small sample effect in a single study.

Positive results are easy to publish in China.

The sample size included in the study was too small to observe the recurrence rate of a large sample population.

The sample size included in the study was too small to observe the incidence of adverse reactions of a large sample population.

Evaluation of the data suggested publication bias, and there may be the equivalent number of 'negative' trials that have not been included in this analysis. GRADE, Working Group Grades of Evidence; SJTs, Sanjin tablets; LTs, levofloxacin tablets; GTs, gatifloxacin tablets; CI, confidence interval; RR, relative ratio.
